Chinese pharmaceutical company Innovent Biologics has signed an out-license agreement with Etana Biotechnologies to develop and commercialise cancer drug BYVASDA (Bevacizumab Biosimilar) in Indonesia.
Thermo Fisher Scientific announced the acquisition of Henogen, a Belgian viral vector manufacturing business belonging to Groupe Novasep, for about €725m ($875m) in cash.
Fujifilm is set to invest about $2bn to build a new large-scale cell culture production site for biopharmaceuticals in the US.
Symbiosis Pharmaceutical Services, a specialist provider of pharmaceutical and vaccine development services, has announced it has signed a supply agreement with AstraZeneca for sterile manufacture of the Covid-19 recombinant adenovirus vaccine known as AZD1222 for AstraZeneca sponsored clinical trials.
Novo Nordisk has agreed to acquire Corvidia Therapeutics, a portfolio company of life sciences venture capital firm Sofinnova Partners, in a deal valued at $2.1bn.
BioCryst Pharmaceuticals has secured a $34.7m contract from the US Centers for Disease Control and Prevention (CDC) for the supply of up to 50,000 doses of its approved antiviral influenza therapy, RAPIVAB (peramivir injection) over a five-year period.
Aurobindo Pharma USA has agreed to acquire selected portions of Sandoz US portfolio from Novartis for $900m of cash and $100m of potential earn-outs.
UK-based EUSA Pharma has agreed to acquire the global rights of Sylvant (siltuximab), a rare blood disorder drug, from Janssen Sciences Ireland UC for $115m.
Clinigen Group has acquired the global rights to Proleukin (aldesleukin, recombinant interleukin-2) outside the United States from Novartis.
Takeda Pharmaceutical’s £45.3bn ($62bn) acquisition of Shire has been unconditionally approved by the US Federal Trade Commission (FTC).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.